Академический Документы
Профессиональный Документы
Культура Документы
Pulmonary arterial hypertsion is an increase in blood pressure in the artery due to the increased pulmonary vascular resistence and right ventricular failure. Puimonary artery carries the bloodfrom the right ventricles to lungs.
Breathlessnesss Dizziness Fainting Non-productive lough Hemoptysis (cough out blood) Swelling around the ankle,knees Chest pain palpitation
SYMPTOMS:
progressive increase
Exertional dyspnea When right ventricular failure sets in, patients start having lower extremity edema from venous congestion. Angina Orthopnea and paroxysmal nocturnal dyspnea (PND) hepatomegaly
Normally PAH is regarded mainly as disease of excess vasoconstriction But these view was incomplete new concets have been developed: In the pathophysiology of PAH Uncheked incresed in the proliferation of smooth muscle cells Dysregulated control of endothelial cell with apoptosis Dysfunction of some areas and profuse proliferation PAH is disease of the precapillary pulmonary arterial blood PAH is panvasculopathy,serum seritonin levels are increased Hence decreasing the vasodilator /vasoconstrictor ratio Prothambic factors including tissue factors are increased
In PAH ,Pulmonary artery smooth muscle cell (PASMC) apoptosis is supressed and proliferation is enhanced Factors involved in PASMC proliferation includes; Mutation of bone morphogenetic protein receptor type2(BMPR2) Mitochondrial metabolic abnormolities De-novo expression of survivin protien Increased expression of seritonin levels Increased expression of platelet derived growth factor receptor Tyrosine kinase activation
BMP are part of the tronsforming growth factor super family(TGF-) TGF- controls vascular remodelling; Cell proliferation Apoptosis Cellular differentiation Collagen and extra cellular matrix turnover
IN FAMILIAL PAH:
A loss function mutation in the BMPR2 It results in Imbalence between the apposing effects TGF- ,BMP signalling, It favours in smooth muscle cell for propliferative and anti apoptopic response in edothelial cells it favours ati proliferativve ad pro apoptopic response These overall effect leads to smooth muscle cell proliferation and endothelial hyperplasia
dysregulated control of endothelial cells with apoptosis leads to plexiform lesions and emboli
PLEXI FORM LESION REPRESENTS: Collection of proliferating endothelial cells Smooth muscle cells Fibroblasts Endothelial progenitor cells
ECG CHEST X-RAY ECHOCARDIOGRAM COMPLETE BLOOD PROFILE TEST BIOMARKERS IMMUNOLOGICAL TESTS SPIRAL CT CHEST PULMONARY ANGIOGRAPHY MRI RIGHT HEART CATHETERIZATION ACUTE VASODIALTING TEST 6 MINUTE WALK TEST
PROSTACYCLINS:
(product of arachidonic acid metabolism) Potent vasodilator of pulmonary and systemic circulation) Inhibits the platelet aggregation In PAH patients these levels are low
EX:
Epoprostenol Treprostinol Iloprost Beraprost
Route of aadministrtion
:IV :SC :Inhalation :Oral
The route of administration depends on the half life and mode of absorption.
Rapid onset of action Short half-life (6mins) dose 2ng/kg/min Adverse effects Flushing, headache, nausea, vomitting
Longer half-life(4hrs) USES shows significant improvement in A) exercise capacity B) Pulmonary dynamics ADVERSE EFFECTS Erythema at infusion site, nausea, vommiting, flushing
Endothelial cells produces endothelian-1 (vasoconstrictor) Receptors ETa and ETb ETa activation causes: increased arterial pressure, sodium retention, postive ionotropy, increases catecholamine release, systemic vasocontrictions. ETb activation causes opposite effects of ETa.
Bosentan: Blocks the ETa and ETb. Dose:125mg It improves the pulmonary heamodyanamics and functional capacity
Sitaxsentan: Blocks ETa. It is not hepatotoxic but a rise in prothrombin time is a frequent sideeffect This is because of inhibition of CYP2C9 P450 enzyme which is involved in the metabolism of warfarin Ambrisentan: Blocks ETa. Dose:5mg Use full in class and class Less hepatotoxicity Adverse effects: Teratogenic and hepatotoxic.
NO:
Potent vasodilator, Inhibits smooth muscle cell proliferation NO is produced by nitric oxide synthase In PAH patients NO levels are low NO effects are mediated by cGMP, which is degraded by phosphodiesterase Hence phosphodiesterase inhibitors are used
Sildenafil: selective PDE-5 ihibitors. Dose:20mg, 3times a day. ITS EFFECTIVE IN: In improving the pulmonary hemodynamics significantly to improve the six minute walk test Other drugs: Tadalafil verdanafil
To maximize efficacy and minimize the toxicity PDI-5 and Prosracyclins (Synergism) Sildinafil with Bosentan accenture the bosentan hepatotoxicity
INVASIVE TECHNIQUE;
ATRIAL SEPTOSTOMY LUNG AND COMBINED HEART LUNG TRANSPLANT PULMONARY THROMBOENDARTERECTOMY
Gene therapy:
BMPR2 replacement
Conclusion:
PAH is a complex condition,and it is heamodynamic abnormalityseen in different disease states Different investigations are essential to diagnose the underlying etiology and to asses the severity Significant improvent in patients treated with: Endothelin receptors blockers Prostanoids PDE-5 inhibitors
THANK YOU